Digest Réseau Comment ça marche
Réseau
/
Sociétés
Bi
Non vérifié

Biogen Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieFinanceManagement/Organisation d'EntrepriseMédecine Santé Bien-être

64 communiqués de presse

Voir tous les communiqués de presse
20/04/2026
Biotechnologie
Management/Organisation d'Entreprise
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
31/03/2026
Biotechnologie
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
30/03/2026
Biotechnologie
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
28/03/2026
Biotechnologie
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
19/03/2026
Biotechnologie
Médecine Santé Bien-être
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
11/03/2026
Biotechnologie
Médecine Santé Bien-être
Annonces Économiques
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
05/03/2026
Biotechnologie
Médecine Santé Bien-être
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
04/03/2026
Biotechnologie
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
11/02/2026
Biotechnologie
Biogen Announces Board Chair Transition
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
04/02/2026
Biotechnologie
Médecine Santé Bien-être
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0